Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

Status unconfirmed

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to explore the safety and efficacy data in clinic patients who have been treated with Natalizumab for more than 60 continuous infusions.

Key facts

Study ID

NCT04964700

Run by

Multiple Sclerosis Center of Northeastern New York

People needed

42

Starts

2021-05-06

Expected to finish

2022-06-01

Last updated by the study team

2022-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Multiple Sclerosis patients treated with long term use of natalizumab--60 or more infusions (5 years)

You may not qualify if…

• Patients who do not have 60 or more infusions (5 years) of Natalizumab.

Where it is running

• Multiple Sclerosis Center of Northeastern New York, P.C. — Latham, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.